Chikungunya -- Honduras
Emergent BioSolutions has reported positive findings from the interim analysis of a phase II clinical trial being conducted to assess its chikungunya virus-like particle (CHIKV-VLP) vaccine candidate.
According to the data, around 98% of the trial subjects who received a single dose of the vaccine generated a neutralising antibody response against the virus by day 7.
The response was observed to be sustained through the 6-month visit.
"The phase II trial assessed the safety and
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?6457494&promed&0
No comments:
Post a Comment